Odd Swarting and Camilla Appelgren contribute to the Seventh Edition of the Life Sciences Law Review

The seventh edition of the Life Sciences Law Review covers a total of 34 jurisdictions, providing an overview of legal requirements of interest to pharmaceutical, biotechnology and medical device industries. Odd and Camilla have contributed with the Swedish chapter.

Judgement by the Swedish Supreme Court (March 2019)

Calissendorff Swarting partner Odd Swarting together with special counsel Alexander Besher and associate Johanna Forsberg, have represented the winning party in a case regarding a challenge of an arbitration award. The matter was adjudicated by the Swedish Supreme Court in a judgement rendered 20 March 2019. 

Calissendorff Swarting achieves top rankings in Chambers Europe 2019

We hare honored to share that five of our partners are acknowledged with top rankings within their respective field and that the firm is recognized as a leading firm within its Life Sciences practice area in the 2019 edition of Chambers Europe – a list of Europe’s best lawyers and law firms.

Judgement by the Swedish Supreme Court (June 2018)

Calissendorff Swarting litigation partner Einar Wanhainen has represented the winning party in a dispute adjudicated by the Swedish Supreme Court in an award rendered 13 June 2018. The dispute was about professional liability for a member of the Swedish Bar Association and will be an important precedent for other professional liability cases.

Leave to appeal granted by the Supreme Administrative Court in a dispute between the Church of Sweden and the National Heritage Board

The Supreme Administrative Court (Sw: Högsta förvaltningsdomstolen) has granted the Church of Sweden (the Diocese of Linköping) leave to appeal in a dispute between the Diocese and the National Heritage Board concerning the legal concept of a “church site” (Sw: kyrkotomt) under the Culture Heritage Act of 1988.

Calissendorff Swarting supports Swedish Orphan Biovitrum AB (publ)

Calissendorff Swarting supports Swedish Orphan Biovitrum AB (publ) (Sobi) legal department with advice and lawyers for a longer period of time. Camilla Appelgren is primarily Calissendorff Swarting’s responsible partner. The assignment involves also Peter Nilsson, Martin Nyberg and other lawyers from the firm.

Sobi is an international specialty healthcare company dedicated to rare diseases with a mission to develop and deliver innovative therapies and services to improve the lives of patients. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm.

Calissendorff Swarting has represented Recipharm AB (publ) in its acquisition of a majority share stake in Indian CMO Nitin Lifesciences Ltd for a purchase price of INR 6,713 million (SEK 824 million)

Calissendorff Swarting has represented Recipharm AB (publ) in the acquisition of 74 per cent of the shares in Nitin Lifesciences Limited, an Indian family owned Contract Manufacturing Organisation (CMO) that produces sterile injectables, for a purchase price of INR 6,713 million (SEK 824 million) on a cash and debt free basis.